Abstract: The compact scent delivery system (300) comprises: —a compact scent delivery device (100, 200), —an air flow mixing unit (400) comprising: 5—an inlet (405) for scented air, configured to be connected to an outlet (125) of scented air of the compact scent delivery device, —an outlet (410) for mixed scented air directed at a smelling port (415), —a conduit (420) connecting the inlet for scented air and the outlet for mixed diluted scent air and 0—at least one element of: —an inlet (425) for fresh air, configured to be connected to a fresh air delivery apparatus, said inlet delivering fresh air into the scented air stream between the inlet for scented air and the outlet for mixed scented air and/or 5—an outlet (430) for waste scented air, configured to be connected to an air flow retrieval apparatus and/or a waste air exhaust, said outlet retrieving scented air from the scented air stream between the inlet for scented air and the outlet for mixed scented air to reduce the air flow either for subsequent dilution

Abstract: Gene therapy vector is for use in the treatment of progressive familiar intrahepatic cholestasis type 3. More specifically, an adeno-associated virus vector includes codon-optimized sequence encoding for the MDR3 isoform A for the treatment of PFIC3.

Abstract: A system or method for carbonating a liquid includes receiving, in a sealed container of a carbonator of a drink dispenser system, a predetermined amount of liquid, identifying a predetermined carbonation level associated with a flavoring material, and setting a target pressure of the sealed container based on the predetermined carbonation level. The target pressure is selected from a plurality of different target pressures. The system or method also can include releasing pressurized carbon dioxide from a carbon dioxide source into the sealed container holding the predetermined amount of the liquid therein until an internal pressure of the sealed container is substantially equal to the target pressure. The system or method can also include dispensing, into a drink container, the flavoring material and the liquid from the sealed container of the carbonator.

Abstract: Described herein is an appliance for making a beverage that can include a pod receiver, a camera oriented to capture an image of a code depicted on the pod, a processor and memory in communication with the processor where the processor includes programmed instructions that cause the processor to analyze a design section of the code.

Abstract: The subject matter described relates to a coaxial ablation probe and method and system for real time monitoring of ablation progress for percutaneous ablation. The probe includes an anode. The probe further includes a size and shape adjustable cathode cage surrounding the anode, the cathode cage includes a plurality of struts. The anode extends coaxially with respect to the struts that form the cathode cage. The cathode cage defines the treatment volume. Probe insertion and ablation progress will be monitored by a magnetic resonance imaging system.

Abstract: The subject matter described relates to a coaxial ablation probe and method and system for real time monitoring of ablation progress for percutaneous ablation. The probe includes an anode. The probe further includes a size and shape adjustable cathode cage surrounding the anode, the cathode cage includes a plurality of struts. The anode extends coaxially with respect to the struts that form the cathode cage. The cathode cage defines the treatment volume. Probe insertion and ablation progress will be monitored by a magnetic resonance imaging system.

Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.